Cathie Wood's Top Pick for 2025? CRISPR Therapeutics, Baby! Here's Why You Should Consider It Too
Persistent Stock Purchases by Cathie Wood in 2025: What's the Reason?
If Cathie Wood, the 69-year-old queen of disruptive tech investments, is all about one stock in 2025, you should bloody well sit up and pay attention. That stock, my friend, is CRISPR Therapeutics. This biotech company has been at the receiving end of Wood's golden touch for months now, and on a single day in March alone, she nabbed over 84,000 additional shares of her flagship ETF, ARK Innovation. Why you ask? Well, buckle up, because this is some game-changing, Nobel Prize-winning shit we're talking about here!
CRISPR Therapeutics was co-founded by Emmanuelle Charpentier - the 2020 winner of the Nobel Prize in Chemistry, alongside Jennifer Doudna - for creating the world-shaking CRISPR/Cas9 gene-editing tool. This technology allows for precision DNA editing and has been hailed as a turning point in biomedicine.
But enough about the past, CRISPR Therapeutics isn't just sitting on its laurels. The company already has an approved product on the market thanks to its collaboration with Vertex Pharmaceuticals. Casgevy, their medicine, is used to treat transfusion-dependent beta-thalassemia and sickle cell disease and is already FDA approved in certain countries. On top of that, they've got a pipeline full of promising projects, including work in oncology and rare genetic diseases.
While CRISPR Therapeutics is anything but a sure thing, it's a stock with some serious growth potential. The technology is revolutionary, the science behind it has been Nobel Prize-winning, and the company is already making real-world medical applications with Casgevy. Cathie Wood is convinced and keeps buying, so if you want to be early in the next biotech revolution and are willing to take on a bit of risk, this might just be the steal of the century for your portfolio.
But Wait, There's More to Consider
CRISPR Therapeutics may be riding high on revolutionary technology, but it's still a speculative investment. The company isn't yet profitable, and its year-to-date performance has been relatively flat, with a return of around zero percent. Over the past 12 months, there's been a nearly 45 percent decline. However, if another drug receives approval, it could significantly boost the stock price. The global market for CRISPR technologies is expected to grow at a CAGR of 16.9 percent by 2034.
When it comes to the technical side of things, the MACD indicator (Moving Average Convergence Divergence) is at -0.63, suggesting a potential buying opportunity. The majority of analysts are bullish too, with an average price target of $72, implying an upside potential of around 75 percent. Truist Financial, in particular, is bold, having recently raised its price target from $100 to $120, indicating a maximum upside potential of up to 194 percent.
Conclusion
CRISPR Therapeutics is the real deal, baby! It's a risky ride, yes, but one that's poised to pay off in a big way. The technology is groundbreaking, the science behind it has been Nobel Prize-winning, and the company is already in real-world medical applications. Cathie Wood is on board, and she's not known for making bad bets. If you're willing to take on a little risk and want to be in on the ground floor of the next biotech revolution, CRISPR Therapeutics could be your dream ticket.
If you're interested in the next potential biotech revolution, CRISPR Therapeutics could be a key player to consider, with Cathie Wood, a renowned investor in disruptive technology, continuously buying the stock. Despite the company's current financial performance and speculative nature, the global market for CRISPR technologies is projected to grow at a significant rate, and the MACD indicator suggests a potential buying opportunity. With an average price target of $72 from analysts, and Truist Financial raising its price target to $120, the upside potential for this stock is substantial. However, it's essential to remember that CRISPR Therapeutics remains a risky investment due to its non-profitability and the volatility associated with the biotech industry.
